{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:09:33Z","timestamp":1790683773566,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T00:00:00Z","timestamp":1554508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00198-019-04947-2","type":"journal-article","created":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T00:27:07Z","timestamp":1554596827000},"page":"1465-1473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis"],"prefix":"10.1007","volume":"30","author":[{"given":"J. -Y.","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bianic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,6]]},"reference":[{"key":"4947_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733","journal-title":"Osteoporos Int"},{"key":"4947_CR2","unstructured":"Office of the Surgeon General (2004) Bone health and osteoporosis: a report of the surgeon general. Available at: \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK45513\/\n                    \n                  . Accessed November 7, 2018"},{"key":"4947_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465\u2013475","journal-title":"J Bone Miner Res"},{"key":"4947_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23\u201357","journal-title":"Osteoporos Int"},{"key":"4947_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for pth-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141\u2013149","journal-title":"Endocrinology"},{"key":"4947_CR6","unstructured":"TYMLOS (abaloparatide) (2017). Radius Health, Inc., Waltham, MA. Available at: \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208743lbl.pdf\n                    \n                  . Accessed November 7, 2018"},{"key":"4947_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, Study Investigators ACTIVE (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722\u2013733","journal-title":"JAMA"},{"key":"4947_CR8","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949\u20132957","journal-title":"J Clin Endocrinol Metab"},{"key":"4947_CR9","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2007) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Available at: \n                    https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-evaluation-medicinal-products-treatment-primary-osteoporosis_en.pdf\n                    \n                  . Accessed November 7, 2018"},{"key":"4947_CR10","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719\u2013748","journal-title":"J Natl Cancer Inst"},{"key":"4947_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"4947_CR12","unstructured":"Servier UK (2017) Servier to cease worldwide production and supply of protelos. Available at: \n                    https:\/\/www.servier.co.uk\/sites\/default\/files\/media\/servier_protelos_medical_industry_pr_final.pdf\n                    \n                  . Accessed November 7, 2018"},{"key":"4947_CR13","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 333:1437\u20131443","journal-title":"N Engl J Med"},{"key":"4947_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","volume":"40","author":"RR Recker","year":"2007","unstructured":"Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L Jr, Stock JL (2007) Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 40:843\u2013851","journal-title":"Bone"},{"key":"4947_CR15","first-page":"1895","volume":"85","author":"I Fogelman","year":"2000","unstructured":"Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. Bmd-mn study group. J Clin Endocrinol Metab 85:1895\u20131900","journal-title":"J Clin Endocrinol Metab"},{"key":"4947_CR16","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1177\/0272989X14545789","volume":"34","author":"YK Tu","year":"2014","unstructured":"Tu YK (2014) Use of generalized linear mixed models for network meta-analysis. Med Decis Mak 34:911\u2013918","journal-title":"Med Decis Mak"},{"key":"4947_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13643-015-0133-0","volume":"4","author":"C Cameron","year":"2015","unstructured":"Cameron C, Fireman B, Hutton B, Clifford T, Coyle D, Wells G, Dormuth CR, Platt R, Toh S (2015) Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev 4:147","journal-title":"Syst Rev"},{"key":"4947_CR18","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"key":"4947_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u2013468","journal-title":"N Engl J Med"},{"key":"4947_CR20","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00198-015-3046-9","volume":"26","author":"SR Davis","year":"2015","unstructured":"Davis SR, Tan A, Bell RJ (2015) Targeted assessment of fracture risk in women at midlife. Osteoporos Int 26:1705\u20131712","journal-title":"Osteoporos Int"},{"key":"4947_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","volume":"24","author":"N Freemantle","year":"2013","unstructured":"Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C (2013) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 24:209\u2013217","journal-title":"Osteoporos Int"},{"key":"4947_CR22","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1210\/jc.2011-3060","volume":"97","author":"MH Murad","year":"2012","unstructured":"Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97:1871\u20131880","journal-title":"J Clin Endocrinol Metab"},{"key":"4947_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1159\/000453138","volume":"40","author":"XC Yang","year":"2016","unstructured":"Yang XC, Deng ZH, Wen T, Luo W, Xiao WF, Zhao RB, Li YS (2016) Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention. Cell Physiol Biochem 40:781\u2013795","journal-title":"Cell Physiol Biochem"},{"key":"4947_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/GME.0000000000000466","volume":"22","author":"L Zhang","year":"2015","unstructured":"Zhang L, Pang Y, Shi Y, Xu M, Xu X, Zhang J, Ji L, Zhao D (2015) Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Menopause 22:1021\u2013102550","journal-title":"Menopause"},{"key":"4947_CR25","unstructured":"Institute for Clinical and Economic Review (2017) Anabolic therapies for osteoporosis in postmenopausal women: effectiveness an value. Available at: \n                    https:\/\/icer-review.org\/wp-content\/uploads\/2016\/11\/CTAF_Osteoporosis_Evidence_Report_061617.pdf\n                    \n                  . Accessed November 7, 2018"},{"key":"4947_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1017\/S0266462312000086","volume":"28","author":"A Morrison","year":"2012","unstructured":"Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, Mierzwinski-Urban M, Clifford T, Hutton B, Rabb D (2012) The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 28:138\u2013144","journal-title":"Int J Technol Assess Health Care"},{"key":"4947_CR27","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","volume":"26","author":"L Karlsson","year":"2015","unstructured":"Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26:2401\u20132411","journal-title":"Osteoporos Int"},{"key":"4947_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1759720X09339551","volume":"1","author":"M Mulgund","year":"2009","unstructured":"Mulgund M, Beattie KA, Wong AK, Papaioannou A, Adachi JD (2009) Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Ther Adv Musculoskelet Dis 1:5\u201311","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"4947_CR29","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1046\/j.1532-5415.2003.51110.x","volume":"51","author":"RS Braithwaite","year":"2003","unstructured":"Braithwaite RS, Col NF, Wong JB (2003) Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 51:364\u2013370","journal-title":"J Am Geriatr Soc"},{"key":"4947_CR30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00198-016-3888-9","volume":"28","author":"RT Burge","year":"2017","unstructured":"Burge RT, Disch DP, Gelwicks S, Zhang X, Krege JH (2017) Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States. Osteoporos Int 28:799\u2013809","journal-title":"Osteoporos Int"},{"key":"4947_CR31","unstructured":"Forteo (teriparatide) (2012) Eli Lilly and Co., Indianapolis, IN. Available at: \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021318s012lbl.pdf\n                    \n                  . Accessed November 7, 2018"},{"key":"4947_CR32","unstructured":"Forteo Teriparatide (rbe) Injection (2015) Eli Lilly Australia Pty Limited, West Ryde NSW. Available at: \n                    https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&t=&q=teriparatide\n                    \n                  . Accessed November 7, 2018"},{"key":"4947_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555\u2013565","journal-title":"N Engl J Med"},{"key":"4947_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","volume":"98","author":"BZ Leder","year":"2017","unstructured":"Leder BZ, Tsai JN, Jiang LA, Lee H (2017) Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (data-follow-up). Bone 98:54\u201358","journal-title":"Bone"},{"key":"4947_CR35","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the data-switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155","journal-title":"Lancet"},{"key":"4947_CR36","first-page":"2129","volume":"85","author":"RS Rittmaster","year":"2000","unstructured":"Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129\u20132134","journal-title":"J Clin Endocrinol Metab"},{"key":"4947_CR37","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-04947-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-04947-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-04947-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T23:16:50Z","timestamp":1586042210000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-04947-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,6]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["4947"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-04947-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,6]]},"assertion":[{"value":"20 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jean-Yves Reginster has provided consultancy to, been an advisory board speaker for, or had grant support from Laboratoires Gen\u00e9vrier, Radius Health, Inc., Laboratoires Servier, Pierre Fabre, Cerin GmbH, Institut Biochimique SA, and Mylan N.V.Florence Bianic, Rosanne Campbell, and Monique Martin are employees of Syneos Health, which was contracted by Radius Health, Inc. to perform this analysis.Setareh A. Williams and Lorraine A. Fitzpatrick are employees of and shareholders in Radius Health, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}